Biodesix to Participate in Upcoming Investor Conferences
Biodesix (NASDAQ: BDSX), a diagnostic solutions company, has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biodesix (NASDAQ: BDSX), a diagnostic solutions company, has announced its participation in two upcoming investor conferences. The company will attend the 22nd Annual Craig-Hallum Institutional Investor Conference for one-on-one meetings on May 28, 2025, in Minneapolis, MN. Additionally, Biodesix will present at the 45th Annual William Blair Growth Stock Conference on June 4, 2025, at 9:20 AM CT in Chicago, IL. The William Blair conference presentation will be available via webcast and can be accessed through the Investors section of Biodesix's website under \"News & Events\".
Details
News Market Reaction – BDSX
The recorded move for BDSX in the trading session of this news was +45.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences:
22nd Annual Craig-Hallum Institutional Investor Conference
1x1 Meetings
Date: Wednesday, May 28, 2025
Location: Minneapolis, MN
45th Annual William Blair Growth Stock Conference
Presentation and 1x1 Meetings
Date and Time: Wednesday, June 4, 2025 at 9:20 AM CT
Location: Chicago, IL
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Contacts:
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
chris.brinzey@icrhealthcare.com
1-339-970-2843
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.